Agios Pharmaceuticals, Inc.
315 articles with Agios Pharmaceuticals, Inc.
-
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
6/13/2022
Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases.
-
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
6/10/2022
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.
-
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
-
Agios Announces Evolution of Research Organization - May 16, 2022
5/16/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the evolution of its research organization.
-
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
5/12/2022
Agios Pharmaceuticals, Inc. announced that clinical and translational data will be presented at the European Hematology Association Annual Congress, hosted virtually and in person in Vienna on June 9-12, 2022.
-
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
5/10/2022
Agios Pharmaceuticals, Inc. announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 10:30 a.m. ET.
-
Agios Reports Business Highlights and First Quarter 2022 Financial Results
5/5/2022
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the first quarter ended March 31, 2022.
-
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
4/21/2022
Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, May 5, 2022, at 8:00 a.m. ET to report its first quarter 2022 financial results and other business highlights.
-
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
4/14/2022
Agios Pharmaceuticals, Inc. today announced that data from the core period of the pivotal Phase 3 ACTIVATE study of PYRUKYND.
-
Agios to Participate in March 2022 Investor Conferences
2/28/2022
Agios Pharmaceuticals, Inc. announced the company is scheduled to present at the following March investor conferences.
-
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021.
-
The FDA has approved Agios Pharmaceuticals' Pyrukynd for a rare type of hemolytic anemia treatment. Continue reading the article to know more about the new drug.
-
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
2/17/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration has approved PYRUKYND® in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia.
-
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
2/10/2022
Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, Feb. 24, 2022, at 8:00 a.m. ET to report its fourth quarter and year end 2021 financial results and other business highlights.
-
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
1/10/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced its anticipated 2022 key milestones and priorities that will drive its transition to a commercial-stage genetically defined disease company and the expansion of its robust clinical and research portfolio.
-
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
-
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
12/22/2021
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
12/13/2021
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO),today reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat on hemoglobin response and transfusion burden reduction in adults with pyruvate kinase (PK) deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.